Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ensartinib in ALK+ NSCLC Previously Treated With Crizotinib
NCT03215693Phase 2Unknown
- Sponsor
- Betta Pharmaceuticals
- Start
- Sep 2017
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ensartinib in non-small cell lung cancer (NSCLC), sponsored by Betta Pharmaceuticals. Status: unknown.
02
Drugs
ensartinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03215693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03215693.